my.bionity.com
With an accout for my.bionity.com you can always see everything at a glance – and you can configure your own website and individual newsletter.
01-20-2012: Sandoz announced that it has initiated two milestone Phase III clinical trials - one for biosimilar filgrastim (Amgen's Neupogen®) in the US market, the other for its global pegfilgrastim development program (Amgen's Neulasta®).
The filgrastim study is to evaluate the efficacy and safety of Sandoz's biosimilar filgrastim versus Neupogen® in breast cancer patients eligible for myelosuppressive chemotherapy treatment. It is expected to support extension of commercialization to the US, the largest global market for biologics. Sandoz's filgrastim biosimilar is already marketed under the brand name Zarzio® in more than 30 countries outside the United States.
The pegfilgrastim study, which is being conducted in breast cancer patients undergoing myelosuppressive chemotherapy treatment, represents the next major step in the Sandoz global biosimilar development program.
In addition to Zarzio, Sandoz markets biosimilar somatropin (Omnitrope®) and epoetin alfa (Binocrit®) in countries across Europe and elsewhere. Omnitrope is also marketed in the US, under a different approval pathway.
As with all its biosimilar development programs, Sandoz has focused on using state-of-the-art analytical techniques and process development to produce molecules that are highly similar to their reference product, prior to launching tailored clinical programs to generate appropriate supportive data.
Contact / Request information
Request further information free of charge:
Watchlist
This is where you can add this news to your personal favourites
Sandoz initiates two more Phase III biosimilar trials
Sandoz announced that it has initiated two milestone Phase III clinical trials - one for biosimilar filgrastim (Amgen's Neupogen®) in the US market, the other for its global pegfilgrastim development program (Amgen's Neulasta®).The filgrastim study is to evaluate the efficacy and safety of ... more
Sandoz announced that it has begun a phase II clinical trial in patients for biosimilar rituximab (Roche's Rituxan® / Mabthera®), a monoclonal antibody indicated in conditions including non-Hodgkin's lymphoma and rheumatoid arthritis.The phase II study in patients suffering from rheumatoid ... more
Sandoz leads the way with first generic version of 'gold standard' anti-thrombotic Lovenox
Sandoz announced the introduction of enoxaparin sodium injection, the first generic version of Lovenox®, in the US. Product shipment began immediately following approval by the US Food and Drug Administration (FDA). According to IMS data enoxaparin sodium injection is the best-selling hosp ... more
Sandoz is a fully integrated partner in development and cGMP production of recombinant peptides and proteins. In the field of microbial fermentation, Sandoz offers production capacity at 1,300L, 3,000L, 13,000L and 40,000L scale. The flexibility of production capabilities and fully integr ... more
Ablynx noted that a paper on a novel tetrameric Nanobody® agonist (TAS266) targeting Death Receptor 5 (DR5), a key receptor target on cancer cells across a number of tumour types, was presented at the American Association for Cancer Research Annual Meeting in Chicago by Novartis. The abilit ... more
Ablynx receives milestone payment as collaborator receives IND approval for a nanobody in oncology
Ablynx announced that it has received a €400,000 milestone payment from its collaboration with Novartis. The payment was triggered by the approval of an Investigational New Drug (IND) application from the U.S. Food and Drug Administration for the Phase I clinical trial for a Nanobody® licen ... more
The Journal of the American Medical Association (JAMA) published a study that shows Bexsero induced a robust immune response against meningococcal B disease in the vast majority of infants vaccinated. These results also show that Bexsero can fit into various vaccination schedules in the fir ... more
We focus on the well-being of companion animals and the health and productivity of farm animals. Our extensive product range provides solutions for the prevention and treatment of various widespread animal diseases and parasite infestations. The majority of these products are available by p ... more
About CHEMIE.DE
CHEMIE.DE Information Service GmbH runs specialist scientific internet portals. The secret to our success? We are familiar with what we publish.
Advertising at CHEMIE.DE
Our advertising formats support you in getting your message across to a clearly defined target audience.
© 1997-2012 CHEMIE.DE Information Service GmbH, All rights reserved
